Pages that link to "Q81276839"
Jump to navigation
Jump to search
The following pages link to Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples (Q81276839):
Displaying 50 items.
- IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma (Q21261901) (← links)
- NFAT promotes carcinoma invasive migration through glypican-6 (Q24336063) (← links)
- Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma (Q26827487) (← links)
- Insidious changes in stromal matrix fuel cancer progression (Q26851261) (← links)
- GPC-3 in hepatocellular carcinoma: current perspectives (Q28066774) (← links)
- Gene expression profiling of liver cancer stem cells by RNA-sequencing (Q28483663) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- Expansion of interferon-gamma-producing multifunctional CD4 T-cells and dysfunctional CD8 T-cells by glypican-3 peptide library in hepatocellular carcinoma patients (Q33850655) (← links)
- Driving CAR T-cells forward (Q34046505) (← links)
- Expression of glypican 3 in placental site trophoblastic tumor (Q34199179) (← links)
- Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn's disease. (Q34227147) (← links)
- Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library (Q34260503) (← links)
- PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. (Q34377342) (← links)
- Glypican-3: A new target for cancer immunotherapy (Q34543102) (← links)
- Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles (Q34675546) (← links)
- Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma (Q35011925) (← links)
- Potential of soluble CD26 as a serum marker for colorectal cancer detection. (Q35113393) (← links)
- Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes (Q35235698) (← links)
- Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC (Q35507495) (← links)
- Expression of Glypican 3 in low and high grade urothelial carcinomas. (Q35552355) (← links)
- Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel (Q35570817) (← links)
- Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters (Q36375383) (← links)
- Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma (Q36524756) (← links)
- Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma (Q36712597) (← links)
- Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma (Q37031710) (← links)
- Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. (Q37122823) (← links)
- Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients (Q37299042) (← links)
- HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models (Q37418634) (← links)
- Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma (Q37538453) (← links)
- Glypican-3 antibodies: a new therapeutic target for liver cancer (Q37625736) (← links)
- Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions (Q37636855) (← links)
- Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. (Q37685728) (← links)
- Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives (Q37766798) (← links)
- Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma (Q37873514) (← links)
- Antithetic roles of proteoglycans in cancer. (Q37941513) (← links)
- Latest developments in precancerous lesions of hepatocellular carcinoma (Q38791960) (← links)
- Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy (Q38877677) (← links)
- Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA). (Q38947665) (← links)
- Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma (Q39924228) (← links)
- T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. (Q40064011) (← links)
- Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager (Q41592942) (← links)
- Hepatocellular tumors: immunohistochemical analyses for classification and prognostication (Q42114895) (← links)
- Suppression of Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-β2 (Q42134157) (← links)
- Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma (Q43509730) (← links)
- Glypican-3 expression in clear cell adenocarcinoma of the ovary (Q44268931) (← links)
- Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity (Q45857417) (← links)
- PKM2 is not required for colon cancer initiated by APC loss. (Q47128334) (← links)
- High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models (Q47608670) (← links)
- Linking Extracellular Matrix Agrin to the Hippo Pathway in Liver Cancer and Beyond. (Q50131782) (← links)
- Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma (Q50543798) (← links)